AI-generated summary
This review summarizes pharmacological, regenerative, biomaterial-based and physical strategies for medication-related osteonecrosis of the jaw, a complication linked mainly to antiresorptive and antiangiogenic drugs. The authors report that some approaches, such as teriparatide and autologous platelet concentrates, have varying degrees of clinical support, while many others rely mainly on preclinical or limited clinical evidence. They conclude that clinical readiness varies and that standardized studies are needed.
- Who or what was studied
- Patients with medication-related osteonecrosis of the jaw (MRONJ), a complication associated mainly with antiresorptive and antiangiogenic therapies
- Limits stated in the abstract
- The authors state that evidence for several approaches remains limited or heterogeneous and that standardized clinical studies are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on spandidos-publications.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photodynamic therapy, Photobiomodulation, Angiogenesis, Inflammation, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.